Antoine Lesur1, Lina Ancheva1, Yeoun Jin Kim1, Guy Berchem2,3, Jan van Oostrum1, Bruno Domon1. 1. Luxembourg Clinical Proteomics Center (LCP), CRP-Santé, Strassen, Luxembourg. 2. Laboratory of Experimental Hemato-Oncology, CRP-Santé, Strassen, Luxembourg. 3. Centre Hospitalier Luxembourg (CHL), Strassen, Luxembourg.
Abstract
PURPOSE: We report an immunocapture strategy to extract proteins known to harbor driver mutations for a defined cancer type before the simultaneous assessment of their mutational status by MS. Such a method bypasses the sensitivity and selectivity issues encountered during the analysis of unfractionated complex biological samples. EXPERIMENTAL DESIGN: Fast LC separations using short nanobore columns hyphenated with a high-resolution quadrupole-orbitrap mass spectrometer have been devised to take advantage of fast MS cycle times in conjunction with sharp chromatographic peak widths to accelerate the sample analysis throughput. Such an analytical platform is well suited to analyze simple protein mixtures obtained after immunoaffinity enrichment. RESULTS: After establishing the technical performance of the platform, the method was applied to the quantitative profiling of cellular Ras and EGFR protein isoforms, as well as serum amyloid A isoforms in plasma. CONCLUSIONS AND CLINICAL RELEVANCE: Immunoaffinity purification combined with fast LC-MS detection for the detection of driver mutations in tissue and tumor biomarkers in plasma samples can assist clinicians to select an optimal therapeutic intervention for patients.
PURPOSE: We report an immunocapture strategy to extract proteins known to harbor driver mutations for a defined cancer type before the simultaneous assessment of their mutational status by MS. Such a method bypasses the sensitivity and selectivity issues encountered during the analysis of unfractionated complex biological samples. EXPERIMENTAL DESIGN: Fast LC separations using short nanobore columns hyphenated with a high-resolution quadrupole-orbitrap mass spectrometer have been devised to take advantage of fast MS cycle times in conjunction with sharp chromatographic peak widths to accelerate the sample analysis throughput. Such an analytical platform is well suited to analyze simple protein mixtures obtained after immunoaffinity enrichment. RESULTS: After establishing the technical performance of the platform, the method was applied to the quantitative profiling of cellular Ras and EGFR protein isoforms, as well as serum amyloid A isoforms in plasma. CONCLUSIONS AND CLINICAL RELEVANCE: Immunoaffinity purification combined with fast LC-MS detection for the detection of driver mutations in tissue and tumor biomarkers in plasma samples can assist clinicians to select an optimal therapeutic intervention for patients.
Authors: Tujin Shi; Ehwang Song; Song Nie; Karin D Rodland; Tao Liu; Wei-Jun Qian; Richard D Smith Journal: Proteomics Date: 2016-08 Impact factor: 3.984
Authors: Tai-Tu Lin; Tong Zhang; Reta B Kitata; Tao Liu; Richard D Smith; Wei-Jun Qian; Tujin Shi Journal: Mass Spectrom Rev Date: 2021-10-31 Impact factor: 9.011
Authors: Song Nie; Tujin Shi; Thomas L Fillmore; Athena A Schepmoes; Heather Brewer; Yuqian Gao; Ehwang Song; Hui Wang; Karin D Rodland; Wei-Jun Qian; Richard D Smith; Tao Liu Journal: Anal Chem Date: 2017-08-11 Impact factor: 6.986
Authors: Hui Wang; Tujin Shi; Wei-Jun Qian; Tao Liu; Jacob Kagan; Sudhir Srivastava; Richard D Smith; Karin D Rodland; David G Camp Journal: Expert Rev Proteomics Date: 2015-12-19 Impact factor: 3.940
Authors: Lennard J M Dekker; Cassandra Verheul; Nicky Wensveen; William Leenders; Martine L M Lamfers; Sieger Leenstra; Theo M Luider Journal: ACS Omega Date: 2022-01-19